Raica Marius, Jitariu Adriana-Andreea, Cimpean Anca Maria
Department of Microscopic Morphology/Histology, Angiogenesis Research Center "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Department of Microscopic Morphology/Histology, Angiogenesis Research Center "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania
Anticancer Res. 2016 Sep;36(9):4427-35. doi: 10.21873/anticanres.10986.
Cutaneous malignant melanoma is an aggressive tumor characterized by early lymph node metastasis and bad prognosis. Although the spread of tumor cells in the regional lymph nodes is very important in the staging, prognosis and therapeutic strategy of malignant melanoma, the mechanism(s) of initial lymphatic vessels invasion is are) not completely understood. In the present review, we analyze the main factors involved in melanoma-associated lymphangiogenesis, based on existing available evidence. Currently, there are no anti-lymphangiogenic drugs approved for clinical trials. On the other hand, inhibition of lymph node metastasis has been demonstrated in experimental models by inhibiting tumor-associated lymphangiogenesis.
皮肤恶性黑色素瘤是一种侵袭性肿瘤，其特征为早期淋巴结转移且预后不良。尽管肿瘤细胞在区域淋巴结中的扩散在恶性黑色素瘤的分期、预后及治疗策略中非常重要，但初始淋巴管侵袭的机制尚未完全明确。在本综述中，我们基于现有证据分析了与黑色素瘤相关的淋巴管生成所涉及的主要因素。目前，尚无获批用于临床试验的抗淋巴管生成药物。另一方面，在实验模型中，通过抑制肿瘤相关的淋巴管生成已证实可抑制淋巴结转移。
